At low concentrations (<25 μM), DMF activates Nrf2 by modifying KEAP1, promoting antioxidant gene expression and cytoprotection, as seen in breast cancer models where it reduces tumor invasion via macrophage modulation. The gene discussed is NFE2L2; the disease is breast carcinoma.